Quantum BioPharma Company Profile - aVenture Research
Quantum BioPharma is a biopharmaceutical company developing Lucid-MS, an investigational drug candidate designed to address demyelination in multiple sclerosis, while building a portfolio of assets for neurodegenerative and metabolic disorders.
The company completed Phase 1 single-ascending-dose and multiple-ascending-dose studies of Lucid-MS in healthy volunteers. Lucid-MS is a patented neuroprotective compound that demonstrated in preclinical models the ability to prevent and reverse myelin degradation, and Quantum BioPharma maintains exclusive worldwide rights to the candidate and a patent portfolio for its continued clinical and commercial development.
Lucid-MS is a patented investigational new chemical entity for multiple sclerosis that preserves myelin in preclinical study without immune suppression.